Skip to content

Myocardial Ischemia After Coronary Sinus Reduction Stent Implantation

Myocardial Ischemia by 15O-H2O PET/CT in Patients With Coronary Artery Disease and Refractory Angina - Evaluation of the Coronary Sinus Reduction Stent Method

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06033495
Acronym
MICS-Reduce
Enrollment
15
Registered
2023-09-13
Start date
2023-12-01
Completion date
2025-06-01
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris

Brief summary

Chronic angina pectoris refractory to medical and revascularization therapies is a disabling medical condition and a major public health problem. Patients with refractory angina have limited treatment options. One proposed therapy modality is transcatheter implantation of a reduction stent in the coronary sinus. Coronary sinus reduction stents have been shown to reduce angina burden considerably and to improve quality of life. The reduction stent is assumed to increase myocardial perfusion and reduce myocardial ischemia, but the mechanism of action is poorly understood. The aim of this project is to assess the myocardial ischemia burden in patients with refractory angina who are undergoing a transcatheter coronary sinus reducer procedure. This is a clinical non-randomized self-controlled cohort study with blinded outcome adjudication for changes in myocardial perfusion. Patients with refractory angina will be systematically examined before implantation of the coronary sinus reduction stent and after 6 months. The primary outcome, changes in myocardial perfusion on the gold standard 15O-H2O PET/CT will be evaluated on blinded perfusion scans where the stent is invisible. To provide context to the findings, we will also evaluate whether changes in myocardial ischemia are associated with less angina and better cardiac function parameters. Effects of stent implantation on angina symptoms and quality of life could be affected by a placebo effect. Treatment options for patients with refractory angina is needed, and results from the present study will explore if coronary sinus reduction stents are improving myocardial ischemia in this patient group. Signs of improved objective perfusion will inspire confidence in the method.

Interventions

DEVICECoronary sinus reduction stent

Percutaneous stent implantation to reduce the dimension of the coronary sinus

Sponsors

Oslo University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Coronary artery disease and refractory angina * Clinical indication for coronary sinus reduction stent implantation * Written informed consent * Anticipated compliance with protocol

Exclusion criteria

* Ineligibility for coronary sinus reduction stent implantation * Lack of informed consent * Not expected to comply with protocol

Design outcomes

Primary

MeasureTime frameDescription
Myocardial ischemia6 monthsChange in myocardial flow reserve on 15O-H2O PET/CT

Secondary

MeasureTime frameDescription
Change in angina burden6 monthsSeattle angina questionnaire (SAQ-7) score ranging 0 (bad) -100 (good) will be assessed at baseline and after 6 months.
Change in quality of life6 monthsKansas City Cardiomyopathy Questionnaire (KCCQ) score ranging 0 (bad) -100 (good) will be assessed at baseline and after 6 months.
Change in exercise capacity6 monthsMaximum oxygen extraction on cardiopulmonary exercise test assessed at baseline and after 6 months.
Change in coronary microcirculation6 monthsInvasive assessment of coronary flow reserve (CFR) at baseline and at 6 months

Contacts

Primary ContactØyvind Lie, MD, PhD
oyvlie@gmail.com+4793429011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026